![]() ![]() ![]() Positive topline data from Journey Medical’s two DFD-29 Phase 3 clinical trials for the treatment of rosacea were reported in July 2023. ![]() Srinivas Sidgiddi, M.D., Vice President, Research & Development at Journey Medical, added, “We anticipate that the NDA for DFD-29 will be submitted to the FDA around year-end and our goal, pending FDA approval, is to achieve a label that portrays the efficacy and safety profile DFD-29 demonstrated during its clinical development.” With all of the unique differentiators DFD-29 brings to the patient, it has the potential to become the best-in-class and the only oral, systemic therapy to address both inflammatory lesions and redness from rosacea, changing the treatment paradigm for this long-term inflammatory skin condition,” said Claude Maraoui, Co-Founder, President and Chief Executive Officer of Journey Medical. ![]() “We are encouraged by the pre-NDA meeting and the progress we have made towards our goal of securing the regulatory review and approval necessary to make DFD-29 available to patients. During the pre-NDA meeting and in the official meeting minutes, the FDA agreed that the proposed data package is sufficient to support the NDA submission, which the Company continues to anticipate will occur around year-end of 2023. The purpose of the meeting was to discuss the 505(b)(2) NDA submission plan for DFD-29 for the treatment of inflammatory lesions (papules and pustules) and erythema of rosacea. DFD-29 is being developed in collaboration with Dr. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company received the official meeting minutes from its pre-New Drug Application (“NDA”) meeting with the FDA for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) to treat rosacea in adults. 06, 2023 (GLOBE NEWSWIRE) - Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |